IPN Share Price

Open 99.27 Change Price %
High 99.90 1 Day 0.59 0.59
Low 99.14 1 Week 4.61 4.84
Close 99.90 1 Month 8.39 9.17
Volume 108097 1 Year 46.38 86.66
52 Week High 101.95
52 Week Low 50.76
IPN Important Levels
Resistance 2 100.60
Resistance 1 100.31
Pivot 99.65
Support 1 99.49
Support 2 99.20
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
ACA 13.76 -0.29%
ACA 13.76 -0.29%
More..
EPA France Top Gainers Stocks
MLCTA 9.70 19.75%
ALALO 0.07 16.67%
APAM 33.78 15.72%
APAM 33.78 15.72%
CARP 57.85 15.70%
MLLOI 3.80 15.15%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
FLO 0.88 -34.81%
FLO 0.88 -34.81%
MLION 0.03 -25.00%
ALTRA 1.23 -14.58%
MLCVG 3781.00 -11.04%
BB 108.50 -10.26%
BB 108.50 -10.26%
BB 108.50 -10.26%
BB 108.50 -10.26%
CBE 259.14 -7.45%
More..

Ipsen (EPA: IPN)

IPN Technical Analysis 5
As on 26th Apr 2017 IPN Share Price closed @ 99.90 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 67.86 & Strong Buy for SHORT-TERM with Stoploss of 87.94 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPN Target for April
1st Target up-side 99.87
2nd Target up-side 104.16
3rd Target up-side 108.45
1st Target down-side 87.65
2nd Target down-side 83.36
3rd Target down-side 79.07
IPN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ipsen.com
IPN Address
IPN
65, quai Georges Gorse
Cedex
Boulogne-Billancourt, 92650
France
Phone: 33 1 58 33 50 00
Fax: 33 1 58 33 50 01
IPN Latest News
Interactive Technical Analysis Chart Ipsen ( IPN EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ipsen
IPN Business Profile
Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.